Review
Infectious Diseases
Hassan Ishaq, Wajeeha Tariq, Khawaja Muhammad Talha, Bharath Raj Varatharaj Palraj, M. Rizwan Sohail, Larry M. Baddour, Maryam Mahmood
Summary: Overall mortality and complicated bacteremia were not significantly associated with high vancomycin MICs in patients with MRSAB. Early mortality was significantly associated with low vancomycin MIC, while mortality in studies using broth microdilution method and need for mechanical ventilation were significantly associated with high vancomycin MIC. Further randomized controlled trials are needed to assess the predictive value of vancomycin MIC values for mortality and other adverse clinical outcomes in patients with MRSAB.
Article
Infectious Diseases
Khawaja M. Talha, Hassan Ishaq, Rommel Ramesh, Wajeeha Tariq, Verda Arshad, Larry M. Baddour, M. Rizwan Sohail, Raj Palraj
Summary: The study aimed to determine the role of high VMIC in predicting clinical outcomes in patients with MRSAB but found that it was not significantly associated with in-hospital mortality, median duration of bacteremia, and metastatic infectious complications. Septic arthritis associated with low VMIC was significant.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2021)
Review
Pharmacology & Pharmacy
Masaru Samura, Yuki Kitahiro, Sho Tashiro, Hiromu Moriyama, Yuna Hamamura, Isamu Takahata, Rina Kawabe, Yuki Enoki, Kazuaki Taguchi, Yoshio Takesue, Kazuaki Matsumoto
Summary: This systematic review and meta-analysis compares the efficacy of daptomycin and vancomycin in adult patients with bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) with a vancomycin minimum inhibitory concentration (MIC) > 1 mu g/mL. The results show that daptomycin treatment is associated with lower mortality and higher treatment success compared to vancomycin, regardless of the vancomycin MIC test method used. Daptomycin should be considered as a treatment option for MRSA bacteremia with a vancomycin MIC > 1 mu g/mL, especially in patients with intermediate- and high-risk bacteremia sources.
Article
Infectious Diseases
Yu Ri Kang, Doo Ryeon Chung, Jae-Hoon Ko, Kyungmin Huh, Sun Young Cho, Cheol-In Kang, Kyong Ran Peck
Summary: This study compared MSSA strains with high and low vancomycin MICs, and identified that mutations in the graR and walK genes may contribute to reduced vancomycin susceptibility in MSSA.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Microbiology
Melissa J. Karau, Suzannah M. Schmidt-Malan, Scott A. Cunningham, Jayawant N. Mandrekar, Bobbi S. Pritt, Tiffany R. Keepers, Alisa W. Serio, Surya Chitra, Robin Patel
Summary: Omadacycline, vancomycin, and rifampin, as well as rifampin combination therapies, were evaluated in an experimental rat model of MRSA osteomyelitis. The results showed that rifampin combination therapy was effective in reducing MRSA recovery without developing resistance. The combination of omadacycline and rifampin yielded negative MRSA detection, suggesting its potential as a treatment for osteomyelitis.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Microbiology
Monika Kumaraswamy, Kamilla Wiull, Bishnu Joshi, George Sakoulas, Armin Kousha, Gustav Vaaje-Kolstad, Mona Johannessen, Kristin Hegstad, Victor Nizet, Fatemeh Askarian
Summary: This study revealed that MRSA-derived MVs are capable of reducing the pathogen's susceptibility to VAN, thereby increasing its resistance to treatment, particularly in interactions with human neutrophils. Additionally, the elevated expression of proteins associated with antibiotic resistance in MVs may further impact MRSA's resistance.
Article
Infectious Diseases
Jin Liang, Yuanfang Hu, Mingxia Fu, Na Li, Fengxia Wang, Xiaojun Yu, Bing Ji
Summary: The study investigated the molecular epidemiology of Staphylococcus aureus (S. aureus) in patients from the Yellow River Delta region and examined antibiotic resistance profiles in different genetic backgrounds. Antibiotic susceptibility testing, spa typing, and agr typing were conducted on all 204 strains. The results identified 39 MRSA strains and 22 hVISA isolates. The majority of MRSA isolates belonged to agrI and were associated with type IV SCCmec. The most common genotypes among MRSA population were ST59-t437-agrI-IVa and ST72-t2431-agrI-IVF. The study highlights the genetic diversity and drug resistance patterns among MSSA strains exhibiting phenotypic hVISA.
INFECTION AND DRUG RESISTANCE
(2023)
Article
Infectious Diseases
Cheng-En Tsai, Chia-Jui Yang, Yu-Chung Chuang, Jann-Tay Wang, Wang-Huei Sheng, Yee-Chun Chen, Shan-Chwen Chang
Summary: This study aimed to determine the synergistic effects of combining CPT with DAP, VAN, or LNZ against different MRSA strains. The results showed that the CPT-DAP combination exhibited significant synergistic bactericidal effects, while the CPT-VAN and CPT-LNZ combinations did not show synergistic activity. Therefore, DAP may be a better choice for combination therapy with CPT in the treatment of MRSA infections.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Wei-Yao Wang, Chen-Feng Chiu, Yuan-Ti Lee, Po-Ren Hsueh, Shih-Ming Tsao
Summary: This study found that VISA was rarely isolated from invasive MRSA infections in Taiwan, and most cases had limited genotypes and corresponding phenotypes.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2022)
Article
Pathology
Jill Parkes-smith, Haakon Bergh, Patrick N. A. Harris
Summary: Staphylococcus aureus bacteraemia has high morbidity and mortality, and timely use of effective antibiotics is crucial. Molecular diagnostics can shorten the time from blood culture positivity to identification of MRSA or MSSA.
Article
Biotechnology & Applied Microbiology
Rong Huang, Guang-Qing Cai, Jian Li, Xi-Sheng Li, Hai-Ting Liu, Xue-Ling Shang, Jian-Dang Zhou, Xin-Min Nie, Rong Gui
Summary: A novel nano-drug delivery system, PLT@Ag-MOF-Vanc, was constructed for the treatment of MRSA infections, showing good antibacterial activity, biocompatibility, and targeting capabilities. It killed MRSA through multiple approaches and demonstrated superior anti-infective effects in a mouse MRSA pneumonia model compared to free vancomycin.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)
Article
Immunology
Yifei Lu, Yingran Wang, Jing Wang, Yan Zhao, Qiu Zhong, Gang Li, Zhifeng Fu, Shuguang Lu
Summary: Endolysin LysP108 demonstrates promising antibacterial potential as it can lyse bacterial cell walls, inhibit bacterial biofilms, and work synergistically with vancomycin to reduce abscess size in MRSA-infected mice. The results indicate strong bactericidal effects against MRSA and the ability to significantly reduce subcutaneous abscess size when used in combination with vancomycin.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Nur Najihah Izzati Mat Rani, Xiang Yi Chen, Zahraa M. Al-Zubaidi, Hanisah Azhari, Tzar Mohd Nizam Khaitir, Pei Yuen Ng, Fhataheya Buang, Geok Chin Tan, Yin Ping Wong, Mazlina Mohd Said, Adeel Masood Butt, Azmy A. Hamid, Mohd Cairul Iqbal Mohd Amin
Summary: This study focused on the encapsulation of vancomycin into liposomes coated with a red blood cell membrane with a targeting ligand, and successfully achieved targeted drug delivery to bacterial cells. The conjugation of the targeting ligand was confirmed through various analyses, and the formulation exhibited controlled drug release. In vitro and in vivo experiments demonstrated the high antibacterial efficacy of the formulation against MRSA, with low toxicity to mammalian cells and human erythrocytes.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2022)
Article
Multidisciplinary Sciences
Pooi Yin Chung, Pey Lin Narissa Loh, Hui-min Neoh, Ramliza Ramli
Summary: Staphylococcus aureus is a significant threat to human health and has developed resistance to conventional antimicrobials. The presence of biofilms complicates treatment for infections caused by multi-drug resistant S. aureus. Alpha-amyrin has been shown to reduce biomass and inhibit metabolic activity of S. aureus. This study demonstrates that alpha-amyrin can reduce biofilm biomass of MSSA, MRSA, and VISA isolates, suggesting its potential as a therapeutic agent for chronic S. aureus infections.
Article
Immunology
Marin L. Schweizer, Kelly Richardson, Mary S. Vaughan Sarrazin, Michihiko Goto, Daniel J. Livorsi, Rajeshwari Nair, Bruce Alexander, Brice F. Beck, Michael P. Jones, Mireia Puig-Asensio, Daniel Suh, Madeline Ohl, Eli N. Perencevich
Summary: Among patients with methicillin-resistant Staphylococcus aureus bloodstream infections, switching to daptomycin is associated with lower 30-day mortality, especially when done within 3 days of initial vancomycin receipt. However, switching to daptomycin at any time during the first hospitalization did not significantly affect 30-day mortality.
CLINICAL INFECTIOUS DISEASES
(2021)
